Bone Marrow Research [43] M. Beyer, M. Kochanek, K. Darabi et al., “Reduced frequencies and suppressive function of CD4CD25 regulatory T cells in patients with chronic lymphocytic leukemia after therapy with ﬂudarabine,” Blood, vol. 106, no. 6, pp. 2018–2025, 2005. [44] C. Galustian, B. Meyer, M. C. Labarthe et al., “The anti-cancer agents lenalidomide and pomalidomide inhibit the prolifera- tion and function of T regulatory cells,” Cancer Immunology, Immunotherapy, vol. 58, no. 7, pp. 1033–1045, 2009. [45] E. Proietti, G. Greco, B. Garrone et al., “Importance of cyclophosphamide-induced bystander eﬀect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice,” Journal of Clinical Investigation, vol. 101, no. 2, pp. 429–441, 1998. [46] S. Brode and A. Cooke, “Immune-potentiating eﬀects of the chemotherapeutic drug cyclophosphamide,” Critical Reviews in Immunology, vol. 28, no. 2, pp. 109–126, 2008. [47] M. E. C. Lutsiak, R. T. Semnani, R. De Pascalis, S. V. S. Kashmiri, J. Schlom, and H. Sabzevari, “Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide,” Blood, vol. 105, no. 7, pp. 2862–2868, 2005. [48] R. P. M. Sutmuller, L. M. Van Duivenvoorde, A. Van Elsas et al., “Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in anti- tumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses,” Journal of Experimental Medicine, vol. 194, no. 6, pp. 823–832, 2001. [49] F. Ghiringhelli, N. Larmonier, E. Schmitt et al., “CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative,” European Journal of Immunology, vol. 34, no. 2, pp. 336–344, 2004. [50] A. P. Castano, P. Mroz, M. X. Wu, and M. R. Hamblin, “Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 14, pp. 5495–5500, 2008. [51] A. M. Ercolini, B. H. Ladle, E. A. Manning et al., “Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response,” Journal of Experimental Medicine, vol. 201, no. 10, pp. 1591–1602, 2005. [52] M. J. Turk, J. A. Guevara-Patin˜o, G. A. Rizzuto, M. E. Engelhorn, and A. N. Houghton, “Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells,” Journal of Experimental Medicine, vol. 200, no. 6, pp. 771–782, 2004. [53] G. Schiavoni, F. Mattei, T. Di Pucchio et al., “Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer,” Blood, vol. 95, no. 6, pp. 2024–2030, 2000. [54] J. Y. Liu, Y. Wu, X. S. Zhang et al., “Single administration of low dose cyclophosphamide augments the antitumor eﬀect of dendritic cell vaccine,” Cancer Immunology, Immunotherapy, vol. 56, no. 10, pp. 1597–1604, 2007. [55] F. Ghiringhelli, C. Menard, P. E. Puig et al., “Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK eﬀector functions in end stage cancer patients,” Cancer Immunology, Immuno- therapy, vol. 56, no. 5, pp. 641–648, 2007. 7 [56] D. Laheru, E. Lutz, J. Burke et al., “Allogeneic granulocyte ma– crophage colony-stimulating factor-secreting tumor immuno- therapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation,” Clinical Cancer Research, vol. 14, no. 5, pp. 1455–1463, 2008. [57] S. Audia, A. Nicolas, D. Cathelin et al., “Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes,” Clinical and Experimental Immunology, vol. 150, no. 3, pp. 523–530, 2007. [58] T. F. Greten, L. A. Ormandy, A. Fikuart et al., “Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-speciﬁc CD4+ T-cell responses in patients with advanced HCC,” Journal of Immunotherapy, vol. 33, no. 2, pp. 211–218, 2010. [59] A. Sharabi and N. H. Ghera, “Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapy,” Advances in Cancer Research, vol. 107, pp. 1–37, 2010. [60] M. J. Smyth and D. I. Godfrey, “NKT cells and tumor immunity—a double-edged sword,” Nature Immunology, vol. 1, no. 6, pp. 459–460, 2000. [61] A. L. Cava, L. V. Kaer, and . Fu-Dong-Shi, “CD4+CD25+ Tregs and NKT cells: regulators regulating regulators,” Trends in Immunology, vol. 27, no. 7, pp. 322–327, 2006. [62] L. Zitvogel, M. Terme, C. Borg, and G. Trinchieri, “Dendritic cell-NK cell cross-talk: regulation and physiopathology,” Current Topics in Microbiology and Immunology, vol. 298, pp. 157–174, 2005. [63] H. Arase, N. Arase, K. Ogasawara, R. A. Good, and K. Onoe, “An NK1.1+ CD48+ single-positive thymocyte subpopulation that expresses a highly skewed T-cell antigen receptor V(β) family,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 14, pp. 6506–6510, 1992. [64] K. Liu, J. Idoyaga, A. Charalambous et al., “Innate NKT lymphocytes confer superior adaptive immunity via tumor- capturing dendritic cells,” Journal of Experimental Medicine, vol. 202, no. 11, pp. 1507–1516, 2005. [65] M. J. Smyth, N. Y. Crowe, Y. Hayakawa, K. Takeda, H. Yagita, and D. I. Godfrey, “NKT cells—conductors of tumor immunity?” Current Opinion in Immunology, vol. 14, no. 2, pp. 165–171, 2002. [66] N. Misra, J. Bayry, S. Lacroix-Desmazes, M. D. Kazatchkine, and S. V. Kaveri, “Cutting Edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells,” Journal of Immunology, vol. 172, no. 8, pp. 4676–4680, 2004. [67] L. Ho¨ltl, R. Ramoner, C. Zelle-Rieser et al., “Allogeneic den- dritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide,” Cancer Immunology, Immunotherapy, vol. 54, no. 7, pp. 663–670, 2005. [68] N. Larmonier, M. Marron, Y. Zeng et al., “Tumor-derived CD4+CD25+ regulatory T cell suppression of dendritic cell function involves TGF-β and IL-10,” Cancer Immunology, Immunotherapy, vol. 56, no. 1, pp. 48–59, 2007.